NASDAQ:CLLS
Cellectis S.A. Stock Predictions
Currently predicting for Thu, 30 Mar 2023Trading levels for CLLS
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 2.08 | 2.13 % | |
| R2 | 2.06 | 1.38 % | ||
| R1 | 2.05 | 0.91 % | ||
| Current price: | 2.04 | |||
| Support | S1 | 2.02 | -0.587 % | |
| S2 | 2.01 | -1.05 % | ||
| S3 | 2.00 | -1.80 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 2.51 | 23.34 % | |
| R2 | 2.38 | 16.95 % | ||
| R1 | 2.25 | 10.57 % | ||
| Current price | 2.04 | |||
| Support | S1 | 1.99 | -2.21% | |
| S2 | 1.95 | -4.18% | ||
| S3 | 1.90 | -6.88% |
CLLS Predictions History
3 years ago
GoldenNugget predicted that
CLLS
for 2019-05-07 is going
$20.11 (-1.28%)
3 years ago
GoldenNugget predicted that
CLLS
for 2019-05-06 is going
$19.89 (-0.56%)
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
